Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Herbalife: Down Mexico Way

The company's stock plummeted Friday after it revealed slowing sales growth in its largest market

Herbalife's (HLF) share price plummeted on Jan. 5, after the Los Angeles-based nutritional supplements-maker warned that it had lower sales growth in Mexico during the fourth quarter ended December 31.

Herbalife thinks its net sales will range between $482.7 million and $484.7 million for the quarter, reflecting a year-over-year increase of at least 18%. The mean analyst estimate had been for $488.3 million revenue during the quarter, according to the San Francisco research firm StarMine, which aggregates data from Thomson Financial.

In the first quarter of 2007, the company expects to have net sales growth between 6% and 10%.

"Our distributors had a tremendously successful year expanding their businesses into new markets and more deeply penetrating existing markets," said CEO Michael O. Johnson in a press release. He thinks the adverse impact of slower sales growth in Mexico during 2007 will be partly offset by growth in other countries such as the U.S.

Investors sold the stock 23.4% to $30.11 on the New York Stock Exchange.

During a conference call with analysts, Herbalife said it now expects flat Mexican sales in 2007. "Not only is Mexico Herbalife's largest market, but we estimate it supplied about half of the total revenue growth in both '05 and '06," said Standard & Poor's equity analyst Loran Braverman. (S&P, like, is owned by The McGraw-Hill Companies.) Braverman cut a 12-month target price by $8 to $35, noting lower expectations of the company's earnings growth in 2007.

blog comments powered by Disqus